Codexis (CDXS) Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (CDXS) today and set a price target of $21.00. The company’s shares closed last Friday at $14.50.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 4.1% and a 36.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.

Currently, the analyst consensus on Codexis is a Moderate Buy with an average price target of $19.50, which is a 32.2% upside from current levels. In a report issued on November 6, Cowen & Co. also maintained a Buy rating on the stock with a $18.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.87 and a one-year low of $8.43. Currently, Codexis has an average volume of 279.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts